Literature DB >> 32240695

Intramacrophage Delivery of Dual Drug Loaded Nanoparticles for Effective Clearance of Mycobacterium tuberculosis.

Priyanka S Jahagirdar1, Pramod K Gupta2, Savita P Kulkarni2, Padma V Devarajan3.   

Abstract

The escalating global burden of tuberculosis necessitates radical strategies to curb its spread. In this study, rifampicin (RIF), a first line anti-tubercular antibiotic and curcumin (CUR), a promising antimycobacterial compound were co-encapsulated in polymeric nanoparticles to achieve intramacrophage delivery and improved Mycobacterium tuberculosis clearance. The dual loaded nanoparticles revealed average size ∼400 nm, low polydispersity and zeta potential of -26.89 ± 2.9 mV. Near complete release of both drugs from nanoparticles in artificial lysosomal fluid proposed drug release after macrophage internalisation. Nanoparticles were nontoxic to RAW 264.7 macrophages and aided 1.5-fold higher drug internalisation compared to free drugs. Enriched intracellular internalisation and lysosomal presence of nanoparticles was ascertained by confocal microscopy. Comparable minimum inhibitory concentration (MIC) of free RIF and CUR and nanoparticle encapsulated RIF and CUR confirmed retention of drug properties. High efficacy against Mycobacterium tuberculosis infected macrophages with RIF-CUR nanoparticles at 25× MIC (98.03 ± 2.5%), with complete clearance above 50× MIC suggests the dual loaded nanoparticles as a promising new nanosystem for tackling tuberculosis.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiinfective(s); Cell culture; Drug-combination particle(s); Nanoparticle(s); Targeted drug delivery

Mesh:

Substances:

Year:  2020        PMID: 32240695     DOI: 10.1016/j.xphs.2020.03.018

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.

Authors:  Anirudh Gairola; Aaron Benjamin; Joshua D Weatherston; Jeffrey D Cirillo; Hung-Jen Wu
Journal:  Adv Ther (Weinh)       Date:  2022-03-09

2.  Inhalable Mannosylated Rifampicin-Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy.

Authors:  Juan M Galdopórpora; Camila Martinena; Ezequiel Bernabeu; Jennifer Riedel; Lucia Palmas; Ines Castangia; Maria Letizia Manca; Mariana Garcés; Juan Lázaro-Martinez; Maria Jimena Salgueiro; Pablo Evelson; Nancy Liliana Tateosian; Diego Andres Chiappetta; Marcela Analia Moretton
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

Review 3.  Nanobiosystems for Antimicrobial Drug-Resistant Infections.

Authors:  Foteini Gkartziou; Nikolaos Giormezis; Iris Spiliopoulou; Sophia G Antimisiaris
Journal:  Nanomaterials (Basel)       Date:  2021-04-22       Impact factor: 5.076

Review 4.  Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis.

Authors:  Amarjitsing Rajput; Satish Mandlik; Varsha Pokharkar
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

Review 5.  Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicals.

Authors:  Samreen Fatima; Anjna Kumari; Ved Prakash Dwivedi
Journal:  MedComm (2020)       Date:  2021-08-05

6.  Preclinical Evidence of Nanomedicine Formulation to Target Mycobacterium tuberculosis at Its Bone Marrow Niche.

Authors:  Jaishree Garhyan; Surender Mohan; Vinoth Rajendran; Rakesh Bhatnagar
Journal:  Pathogens       Date:  2020-05-13

Review 7.  Therapeutic Potential of Curcumin as an Antimycobacterial Agent.

Authors:  Nilakshi Barua; Alak Kumar Buragohain
Journal:  Biomolecules       Date:  2021-08-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.